Hanf, D., Heining, C., Laaber, K., Nebelung, H., Uhrig, S., Hutter, B., . . . Folprecht, G. (2021). Response to cabozantinib following acquired entrectinib resistance in a patient with ETV6-NTRK3 fusion-positive carcinoma harboring the NTRK3G623R solvent-front mutation. JCO precision oncology, 5, . https://doi.org/10.1200/PO.20.00278
Chicago-Zitierstil (17. Ausg.)Hanf, Dorothea, et al. "Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient with ETV6-NTRK3 Fusion-positive Carcinoma Harboring the NTRK3G623R Solvent-front Mutation." JCO Precision Oncology 5 (2021). https://doi.org/10.1200/PO.20.00278.
MLA-Zitierstil (9. Ausg.)Hanf, Dorothea, et al. "Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient with ETV6-NTRK3 Fusion-positive Carcinoma Harboring the NTRK3G623R Solvent-front Mutation." JCO Precision Oncology, vol. 5, 2021, https://doi.org/10.1200/PO.20.00278.